Magic mushroom ingredient psilocybin gains breakthrough therapy designation
October 26, 2018Medical Communications Breakthrough Therapy Designation, Compass, FDA, Magic mushrooms, psylicobin
The US Food and Drug Administration (FDA) has given psilocybin – the psychoactive ingredient in ‘magic mushrooms’ – breakthrough therapy …
GSK opens £54m API plant in Montrose, Scotland
October 25, 2018Manufacturing and Production API, GSK, Scotland, manufacturing, montrose
British multinational GlaxoSmithKline has opened an API manufacturing plant in Montrose Scotland for its Ellipta respiratory medicines. The new facility …
Amgen slashes price of cholesterol drug Repatha by 60%
October 25, 2018Sales and Marketing Repatha, cholestrol, drug, medicine, pricing
American multinational Amgen has slashed the price of cholesterol drug Repatha, reducing the medication’s US list price by 60%. The …
FDA generics approvals up 90% compared to 2014
October 25, 2018Sales and Marketing FDA, Trump, generics, pharma
Continuing to build on its successes in toppling previous benchmarks, it has emerged that the FDA’s total number of generic …
Measles outbreak threatens to decimate isolated Amazonian tribe in Venezuela and Brazil
October 25, 2018Medical Communications Brazil, Venezuela, measles, tribe, vaccines, yanomami
An outbreak of measles threatens to decimate an isolated tribe in the Amazon, according to the non-profit organisation Survival International. …
First novel, single-dose flu drug approved in US in almost 20 years
October 25, 2018Sales and Marketing FDA, Shionogi, Xofluza, flu, influenza, pharma
The FDA has announced that it has approved the first single-dose flu drug with a novel mechanism of action in …
UCB and Biogen’s lupus drug falls short at Phase 2b
October 24, 2018Research and Development Biogen, Lupus, UCB, dapirolizumab pegol, pharma, systemic lupus erythematosus, trial falure
The partnership of UCB and Biogen announced disappointing news, confirming that its experimental therapy dapirolizumab pegol (DZP) failed to meet …
New $2 million programme aims at increasing diversity in cancer research
October 24, 2018Research and Development Cancer, USA, black, cancer research, diversity, latino, native american
The National Cancer Institute are developing a joint cancer drug discovery and development, and research education programme focused towards the …
Pfizer & Lilly’s non-opioid drug reduces pain in osteoarthritis
October 24, 2018Research and Development Eli Lilly, Pfizer, osteoarthritis, pharma
Pfizer and Eli Lilly have announced data revealing that their nerve growth factor (NGF) inhibitor tanezumab met all three of …
Industry leaders warn public may have to stockpile medicines in case of no-deal Brexit
October 24, 2018Research and Development brexit, no-deal Brexit, stockpiling
Martin Sawer, the executive director of the Healthcare Distribution Association (HDA) – formerly the British Association of Pharmaceutical Wholesalers (BAPW) …
Guangdong bans transportation of pigs due to African swine fever outbreak in Hunan
October 23, 2018Research and Development ASF, African swine fever, China, Guangdong, Hunan, animal health
Chinese authorities have banned the transportation of live pigs from Guangdong to other regions, after reports of African swine fever …
Roche’s Alecensa topples Pfizer’s Xalkori in Asian patients with ALK+ advanced lung cancer
October 23, 2018Manufacturing and Production, Research and Development Alecensa, Cancer, ESMO 2018, Roche, lung cancer, pharma
Following up on the reveal of data concerning its immunotherapy Tecentriq in combination with chemotherapy in the treatment of non-small …
First-line Keytruda shows better overall survival in head & neck cancer
October 23, 2018Manufacturing and Production, Research and Development Cancer, ESMO 2018, MSD, head and neck cancer, keytruda, pharma
MSD’s Keytruda (pembrolizumab) made an impact at the European Society for Medical Oncology 2018 Congress as the company unveiled new …
Shares in Mirati plummet after disappointing Phase II trial
October 23, 2018Manufacturing and Production Cancer, Mirati, leuakemia, plummet, stocks
Shares in the California-based biotech Mirati Therapuetics plummeted on Monday after the company released disappointing results from their Phase II …
UK Dementia partnership offering £100,000-200,000 awards for dementia research projects
October 23, 2018Manufacturing and Production Alzheimer's, dementia, development, research
The Dementia Discovery Fund (DDF) in partnership with the UK Dementia Research Institute (UK DRI) has announced that it will …
J&J announce promising Phase 1/2a results for HIV vaccine
October 23, 2018Manufacturing and Production AIDS, HIV, J&J, JJ, Vaccine, infectious diseases
The world may be one step closer to discovering a preventative vaccine for HIV following American multinational Johnson & Johnson’s …
Roche’s Tecentriq+chemo boosts survival in first-line non-small cell lung cancer
October 22, 2018Research and Development, Sales and Marketing Cancer, Roche, lung cancer NSCLC, pharma, tecentriq
Roche joined other major players like Bristol-Myers Squibb in revealing strong data on their cancer immunotherapies at the European Society …
Working Life: Joe Wiley, CEO, Amryt Pharma
October 22, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amryt Pharma, CEO, Ireland, Joe WIley, pharma
Pharmafocus talked to Joe Wiley, CEO and founder of Amryt Pharma as he retraced his journey from medical student in …
Takeda’s subcutaneous vedolizumab proves efficacious in Phase III trial for Ulcerative Colitis
October 22, 2018Sales and Marketing Takeda, UC, biologic, phase III, results, ulcerative colitis, vedolizumab
Japanese pharma firm Takeda has announced that the gut-selective biologic vedolizumab when taken as a subcutaneous (SC) injection, proved efficacious …
Janssen’s Tremfya maintains skin clearance after 3 years in plaque psoriasis
October 22, 2018Research and Development, Sales and Marketing Janssen, Tremfya, pharma, plaque psoriasis, psoriasis
Janssen has revealed new long-term data for its IL-23 inhibitor Tremfya (guselkumab) in moderate to severe plaque psoriasis, demonstrating skin …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
